As new treatment options are developed to reduce the risk of breast and ovarian cancer in women who carry the BRCA1 or BRCA2 genetic mutation, it will become increasingly important to understand women’s preferences for risk-reducing treatment. The gene discussed is BRCA2; the disease is ovarian cancer.